European CHMP recommends license extension of enzalutamide (Xtandi) for treatment of prostate cancer

The proposed license extension is for the treatment of adult men with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy. It is currently licensed for several scenarios in castration resistant prostate cancer only.

European Medicines Agency